SEC Form 4 · accession 0001209191-15-048134
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Riching
Officer — Chief Financial Officer
Period of report
May 28, 2015
Accepted (ET)
May 29, 2015 · 9:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $1.43 | May 28, 2015 | A | 150,000 | A | — | May 28, 2025 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1Ms. Riching was awarded options to purchase shares of OXiGENE, Inc. common stock, $0.01 par value per share (the "Stock Options"), pursuant to the OXiGENE, Inc. 2015 Equity Incentive Plan in connection with her service as Chief Financial Officer.
- F225% of the Stock Options vest immediately, and the remainder will vest in 36 substantially equal monthly installments beginning on the one month anniversary of the grant date.